Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice.

Ruffini, F; Furlan, R; Poliani, P L; Brambilla, E; Marconi, P C; Bergami, A; Desina, G; Glorioso, J C; Comi, G; Martino, G

Ruffini, F; Furlan, R; Poliani, P L; Brambilla, E; Marconi, P C; Bergami, A; Desina, G; Glorioso, J C; Comi, G; Martino, G.

Affiliation

Ruffini F; Neuroimmunology Unit, Department of Neuroscience, DIBIT-San Raffaele Scientific Institute, Milano, Italy.

Gene Ther ; 8(16): 1207-13, 2001 Aug.

Article in En | MEDLINE | ID: mdl-11509953

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy / Fibroblast Growth Factor 2 / Encephalomyelitis, Autoimmune, Experimental Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals Language: En Journal: Gene Ther Journal subject: GENETICA MEDICA / TERAPEUTICA Year: 2001 Document type: Article Affiliation country: Italia Country of publication: Reino Unido

Search on Google

Add to My VHL

XML

PubMed Links